Furthermore, our investigation unveiled diverse cellular and molecular stratifications among colon cancer patients, suggesting that the high-score group derive substantial advantages from dual inhibition of PI3K and mTOR by PI-103. This evidence concerns the gene MTOR and colonic neoplasm.